Detalles de la búsqueda
1.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447003
2.
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.
Gastric Cancer
; 27(1): 6-18, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37847333
3.
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Int J Cancer
; 153(10): 1726-1733, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37455496
4.
Neoadjuvant and adjuvant approaches in gastroesophageal cancers.
Curr Opin Oncol
; 35(4): 318-325, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37222198
5.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC Cancer
; 23(1): 561, 2023 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37337155
6.
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
BMC Cancer
; 21(1): 1158, 2021 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34715810
7.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Int J Cancer
; 147(9): 2493-2502, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32339253
8.
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
BMC Cancer
; 20(1): 886, 2020 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32933498
9.
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
BMC Cancer
; 20(1): 503, 2020 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487035
10.
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Eur J Cancer Care (Engl)
; 29(2): e13213, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883156
11.
Current status of immunotherapy in gastrointestinal malignancies.
Z Gastroenterol
; 58(6): 542-555, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32018315
12.
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
Gastric Cancer
; 27(3): 401-425, 2024 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38386238
13.
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017]. / ASCO- und ESMO-Update 2017 Neuigkeiten vom 53. Meeting der American Society of Clinical Oncology/ASCO 2017 und European Society for Medical Oncology/ESMO-Congress 2017.
Z Gastroenterol
; 56(4): 384-397, 2018 04.
Artículo
en Alemán
| MEDLINE | ID: mdl-29642252
14.
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
BMC Cancer
; 17(1): 893, 2017 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282088
15.
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Chemotherapy
; 62(1): 62-70, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-27643822
16.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27776843
17.
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
Gastric Cancer
; 17(2): 213-25, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24048758
18.
S3-Leitlinie Magenkarzinom Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs Langversion 2.0 August 2019. AWMF-Registernummer: 032/009OL.
Z Gastroenterol
; 57(12): 1517-1632, 2019 12.
Artículo
en Alemán
| MEDLINE | ID: mdl-31826284
19.
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments.
Cancers (Basel)
; 16(7)2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611014
20.
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol
; 42(4): 410-420, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37963317